Find Alternatives To Endologix AFX For Treating Abdominal Aortic Aneurysms, FDA Advises
Executive Summary
In its most recent update on the use of Endoglox AFX endovascular grafts, the US FDA is advising physicians use other devices for treating patients with abdominal aortic aneurysms (AAA). AFX still poses bleeding risk.
You may also be interested in...
FDA Stresses Need For Routine Monitoring Of Endovascular Aortic Repair Patients
A new letter to providers says that to ensure potential adverse events can be identified early, patients should be checked via imaging at 30 days after surgery and at least once a year thereafter.
Bleeding Risks Still A Concern For Patients With Endologix Stent Grafts: FDA Advisory Panel
The US agency’s Circulatory System Devices Panel found type III endoleaks are still a problem for abdominal aortic aneurysm patients treated with the newest Endologix stent graft, though for some the benefits still outweigh the risks. The panel advised that all patients, however, should continue getting annual screenings.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.